SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: (vic-)trastuzumab duocarmazine|DRUG: Physician's choice
Sponsor: Byondis B.V.